Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Emily Drabant Conley
AddedMar 31, 2024
UpdatedMay 31, 2026
Emily Drabant Conley

Emily Drabant Conley

CEO, Federation Bio

CrunchbaseLinkedIn

Emily Drabant Conley's Career

Federation Bio
Federation Bio

South San Francisco, CA, US

CEO· C-Suite · Management
Medrio
Medrio

San Francisco, CA, US

Board Member· Board
Tmrw Life Sciences
Tmrw Life Sciences

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Emily Drabant Conley's Career

Federation Bio
Federation Bio
Series A$50M462019South San Francisco, CA, US
CEO· C-Suite · Management

Recent news

Indian drone startup Raphe mPhibr raises $100M as military UAV demand soarsTechCrunch · 2025

Leadership at Federation Bio

Patrick ZhangPatrick ZhangBoard Member
Racquel BrackenRacquel BrackenCo-Founder
Bryan RobertsBryan RobertsBoard Member
Dylan DoddDylan DoddCo-Founder
John StuelpnagelJohn StuelpnagelBoard Member
Michael FischbachMichael FischbachBoard Member

Similar to Federation Bio

Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
MarvelBiomeMarvelBiomeWoburn, MA, USTherapeuticsest. 2019MarvelBiomeWoburn, MA, US · est. 2019

MarvelBiome: A biopharmaceutical company harnessing microbial power for innovative disease treatments.

Seed · $3.1M9
Naked BiomeNaked BiomeCacheu Region, GWTherapeuticsest. 2015Naked BiomeCacheu Region, GW · est. 2015

Naked Biome: A therapeutics company advancing microbiome-based treatments for skin diseases.

Seed · $11.1M1
Microbiome TherapeuticsMicrobiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30
Medrio
Medrio
Series C$32M2262005San Francisco, CA, US
Board Member· Board

Leadership at Medrio

Mike NovotnyMike NovotnyBoard Member
Nicole DuPont LatimerNicole DuPont LatimerCEO

Similar to Medrio

MedableMedablePalo Alto, CA, USClinical Researchest. 2015MedablePalo Alto, CA, US · est. 2015

Medable: Accelerating therapies with a global cloud platform for efficient clinical research.

Series D · $506.6M750
Clinical Research IOClinical Research IOBoston, MA, USClinical Trials Softwareest. 2016Clinical Research IOBoston, MA, US · est. 2016

Health tech firm, CRIO, revolutionizes clinical trials with integrated eSource and CTMS solutions.

Seed · $19M83
Endpoint ClinicalEndpoint ClinicalSan Francisco, CA, USClinical Trial Softwareest. 2009Endpoint ClinicalSan Francisco, CA, US · est. 2009

Study software provider, Endpoint, designs and tests interactive data access platforms via phones.

Seed · $1.7M606
ClinCaptureClinCaptureSan Francisco, CA, USClinical Trial Softwareest. 2013ClinCaptureSan Francisco, CA, US · est. 2013

ClinCapture: Streamlining clinical trials with cost-effective, privacy-focused software solutions.

Seed · $1.5M26
Tmrw Life Sciences
Tmrw Life Sciences
Angel$153.5M1072018New York City, NY, US
Board Member· Board

Leadership at Tmrw Life Sciences

Jeffrey PortJeffrey PortCo-Founder
Tara ComonteTara ComonteBoard Member
Joshua AbramJoshua AbramBoard Member
Alan MurrayAlan MurrayBoard Member
Louis VillalbaLouis VillalbaCEO

Similar to Tmrw Life Sciences

Conceivable Life SciencesConceivable Life SciencesNew York City, NY, USFertility Treatmentsest. 2022Conceivable Life SciencesNew York City, NY, US · est. 2022

Conceivable Life Sciences: Automating IVF labs for accessible fertility treatments.

Seed · $20M12
Overture LifeOverture LifeNew York City, NY, USFertility Treatments, IVFest. 2017Overture LifeNew York City, NY, US · est. 2017

Overture Life, a biotech firm, innovates IVF through automation and non-invasive selection, making fertility treatments affordable and reliable.

Series B · $45M42
Darwin LifeDarwin LifeNew York City, NY, USIVF Technologyest. 2015Darwin LifeNew York City, NY, US · est. 2015

Darwin Life, a biotech firm, innovates in vitro fertilization tech to reverse aging effects on oocytes and prevent diseases.

Pre-Seed · $1M6
AlifeAlifeSan Francisco, CA, USAI Softwareest. 2020AlifeSan Francisco, CA, US · est. 2020

Alife Health: Pioneering AI tools for modern IVF systems, partnering with top institutions for healthier children.

Series A · $31.5M80

Emily Drabant Conley's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · Kakao

People Similar to Emily Drabant Conley

Anirvan GhoshAnirvan GhoshBoard Member · Unity BiotechnologyJames M. BowerJames M. BowerBoard Member · NumedeonKevin TraceyKevin TraceyCEO · Feinstein Institute for Medical ResearchWilliam MobleyWilliam MobleyBoard Member · UC San DiegoAdam GazzaleyAdam GazzaleyCo-Founder · Jazz Venture PartnersWilliam AlaynickWilliam AlaynickCo-Founder · Arima Genomics